Sogroya (Somapacitan) long-term safety and effectiveness assessed in Japanese adults with severe AGHD

Adult Growth Hormone Deficiency (AGHD) is a chronic condition characterized by insufficient growth hormone (GH) production, leading to impaired body composition, reduced bone mineral density, and diminished quality of life. Traditional daily GH replacement therapies can be burdensome, impacting patient adherence. Sogroya (somapacitan), a long-acting human growth hormone analog, offers a once-weekly dosing regimen, aiming to improve convenience and compliance. However, long-term safety and effectiveness data from real-world clinical practice, especially in specific populations like severe AGHD patients in Japan, are crucial to fully understand its profile beyond controlled clinical trials.

This multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study is investigating the long-term safety and effectiveness of Sogroya (somapacitan) in adults diagnosed with severe AGHD in Japan. Participants are enrolled after a clinical decision to initiate treatment with commercially available Sogroya has been made, reflecting normal clinical practice. The study duration for each participant is approximately 2 to 5 years, depending on their enrollment timing. Data collection focuses on long-term safety outcomes, effectiveness measures, and patient-reported quality of life, utilizing standard clinical assessments and questionnaires.

As an ongoing post-marketing surveillance study, specific long-term safety and effectiveness data for Sogroya (somapacitan) are not yet available. The study is currently enrolling participants and will collect real-world data over a period of 2 to 5 years per patient to assess outcomes under routine clinical practice conditions. Results regarding adverse events, treatment efficacy, and quality of life improvements are pending the completion and analysis of this extensive observational period.